Leerink Partners Has Lowered Expectations for Medpace (NASDAQ:MEDP) Stock Price

Medpace (NASDAQ:MEDP) had its price objective dropped by investment analysts at Leerink Partners from $575.00 to $485.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “market perform” rating on the stock. Leerink Partners’ price target would indicate a potential upside of 16.58% from the stock’s current price.

A number of other brokerages also recently commented on MEDP. Barclays lifted their target price on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. BMO Capital Markets initiated coverage on shares of Medpace in a report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price target for the company. Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective on the stock in a report on Tuesday. TD Cowen reiterated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Finally, Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Three analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Medpace has an average rating of “Hold” and an average target price of $477.36.

Medpace Price Performance

Shares of Medpace stock opened at $416.04 on Wednesday. Medpace has a 1-year low of $250.05 and a 1-year high of $628.92. The stock has a market cap of $11.81 billion, a P/E ratio of 27.19, a P/E/G ratio of 1.37 and a beta of 1.42. The stock’s 50 day simple moving average is $569.92 and its 200-day simple moving average is $537.90.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same period in the prior year, the business earned $3.67 EPS. The firm’s quarterly revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts expect that Medpace will post 12.29 EPS for the current fiscal year.

Insider Activity

In related news, CEO August J. Troendle sold 59,025 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the transaction, the chief executive officer directly owned 774,602 shares in the company, valued at $470,787,603.56. This trade represents a 7.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This represents a 42.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 270,533 shares of company stock worth $163,122,826. 20.30% of the stock is owned by corporate insiders.

Institutional Trading of Medpace

Several hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC raised its position in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Wasatch Advisors LP increased its stake in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the period. Mawer Investment Management Ltd. raised its holdings in Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after acquiring an additional 121,213 shares in the last quarter. Geode Capital Management LLC raised its holdings in Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its stake in Medpace by 12.0% in the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after acquiring an additional 62,503 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.